

Special Issue

Advances in Cancer Immunotherapy and Vaccines Research: 2nd Edition

Message from the Guest Editor

Immunotherapy is now a standard therapy in addition to surgery, chemotherapy, and radiotherapy for treating cancer. Immune checkpoint blockades are a form of immunotherapy that have acceptable results in many types of tumors. However, it only works for around 20% of patients, as it depends on the immune cells already present in the tumor microenvironment. If these cells are lacking or exhausted, the treatment is not effective. Tumor vaccines can help by increasing the number of antitumor immune cells, including CD8 T cells and CD4 T cells. Peptide epitopes from tumor-associated antigens (TAAs) can be used to develop a tumor vaccine. In the past, vaccines using tumor-derived peptides and inadequate adjuvants (such as incomplete Freund's adjuvant) failed to achieve clinical antitumor effects. However, with improvements in our understanding of the immune system, we can now use peptides, costimulatory molecules, and cytokines in combination with adequate adjuvants to expand T cells and impede the immune-suppressive environment. This Special Issue will gather the latest advances in the field of tumor immunology to optimize tumor vaccines.

Guest Editor

Dr. Takumi Kumai

Department of Otolaryngology Head and Neck Surgery, Asahikawa Medical University, Midorigaoka East 2-1-1, Asahikawa, Hokkaido 0788510, Japan

Deadline for manuscript submissions

20 March 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/197302

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).